FDA-cleared profile

QP-Prostate® CAD

Quibim S.L. · MRI · FDA-cleared (510(k))

Authorized purpose: QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.

Clinical role
Concurrent detection and diagnostic support
Images and patients
MRI · Prostate
Key limitation
Keep in mind: Concurrent adjunctive support only; patient-management decisions should not be based solely on QP-Prostate CAD output.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Prostate Input: Bi-parametric prostate MRI consisting of T2-weighted and diffusion-weighted series from patients above 40 years; the FDA dataset includes 1.5T and 3T GE, Siemens, and Philips systems.
  • Who uses it?Intended users: Properly trained physicians, including radiologists, urologists, and physicians qualified to interpret prostate MRI under PI-RADS practice
  • What does the software produce?Output: Two-color overlay markings around suspected prostate lesions, distinguishing moderate and high suspicion for clinically significant cancer (Gleason score 7 or greater), returned in standard DICOM formats for third-party workstations and PACS.
  • What is its most important limitation?Key limitation: Concurrent adjunctive support only; patient-management decisions should not be based solely on QP-Prostate CAD output.

Clinical takeaway. Clinical role: QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.

Evidence takeaway. Evidence from the reviewed source record: Pivotal validation used 228 prostate MRI cases from multiple U.S. centers, with a nine-reader aided/unaided study; standalone lesion-level analysis included 247 lesions.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Concurrent detection and diagnostic support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Bi-parametric prostate MRI consisting of T2-weighted and diffusion-weighted series from patients above 40 years; the FDA dataset includes 1.5T and 3T GE, Siemens, and Philips systems.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Two-color overlay markings around suspected prostate lesions, distinguishing moderate and high suspicion for clinically significant cancer (Gleason score 7 or greater), returned in standard DICOM formats for third-party workstations and PACS.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult prostate MRI; patients above 40 years of age
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Properly trained physicians, including radiologists, urologists, and physicians qualified to interpret prostate MRI under PI-RADS practice
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Concurrent adjunctive support only; patient-management decisions should not be based solely on QP-Prostate CAD output.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Pivotal validation used 228 prostate MRI cases from multiple U.S. centers, with a nine-reader aided/unaided study; standalone lesion-level analysis included 247 lesions.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Pivotal validation used 228 prostate MRI cases from multiple U.S. centers, with a nine-reader aided/unaided study; standalone lesion-level analysis included 247 lesions.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Standalone lesion-level sensitivity was 67.7% for high suspicion and 79.5% for high plus moderate suspicion in the FDA analysis.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported specificity
The FDA standalone analysis reported 0.417 false positives per case for high suspicion and 0.855 for high plus moderate suspicion; reader-study aided AUC was 0.868 versus 0.849 unaided.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

Standalone AUC

0.732 AUC

  • EndpointLesion-level prostate cancer detection
  • Population247 lesions from 228 prostate MRI cases
  • Tested versionQP-Prostate CAD submitted in K242683; build not stated

Reader-study aided AUC

0.868 AUC

  • EndpointReader-study interpretation with QP-Prostate CAD aid
  • Population228 cases interpreted by nine readers
  • Tested versionQP-Prostate CAD submitted in K242683; build not stated

Reader-study AUC improvement

0.019 AUC difference

  • EndpointAided versus unaided reader study
  • Population228 cases interpreted by nine readers
  • Tested versionQP-Prostate CAD submitted in K242683; build not stated

QP-Prostate CAD pivotal standalone and reader study

  • DesignMulticenter standalone lesion analysis and nine-reader aided/unaided study
  • Population228 prostate MRI cases from multiple U.S. centers; standalone analysis included 247 lesions and reader study used nine readers
  • Scopeexact submission
  • Tested versionQP-Prostate CAD submitted in K242683; build not stated
  • Samplen=228
  • IndependenceIndependence not established

K242683

Cases included biopsy/pathology or follow-up reference categories and 1.5T/3T systems from GE, Siemens, and Philips.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Bi-parametric prostate MRI consisting of T2-weighted and diffusion-weighted series from patients above 40 years; the FDA dataset includes 1.5T and 3T GE, Siemens, and Philips systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD

  2. Routing

    Source context, not route validation: The FDA submission describes standard DICOM overlays returned to third-party workstations and PACS; local PACS and fusion-biopsy compatibility require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Two-color overlay markings around suspected prostate lesions, distinguishing moderate and high suspicion for clinically significant cancer (Gleason score 7 or greater), returned in standard DICOM formats for third-party workstations and PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD

  5. Viewer/worklist/report

    Unresolved route: Two-color overlay markings around suspected prostate lesions, distinguishing moderate and high suspicion for clinically significant cancer (Gleason score 7 or greater), returned in standard DICOM formats for third-party workstations and PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA submission describes standard DICOM overlays returned to third-party workstations and PACS; local PACS and fusion-biopsy compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-06
Security
Quibim's security and privacy statement describes an ISO 27001-certified information security management system and ISO 13485-certified quality management system; QP-Care platform data hosted on Microsoft Azure protected by multi-factor authentication and encryption in transit and at rest; pseudonymization of processed data; regular penetration tests following OSSTMM and OWASP methodologies; staff security training and confidentiality obligations.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants ('QUIBIM S.L.', 'Quibim S.L.') are bridged via the identical distinctive name and QP product naming. Exact-release scope is not established.

DICOM/PACS overlay workflow

The exact submission describes moderate/high suspicion lesion overlays returned in DICOM to third-party workstations and PACS.

exact submission · checked 2026-09-06

Quibim family prostate workflow

Quibim's official QP-Prostate page describes prostate segmentation, lesion detection, PI-RADS structured reporting, DICOM, PACS, and fusion-biopsy integration; current exact K242683 compatibility and build require confirmation.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242683
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Prostate
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-18
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Quibim QP-Prostate reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K242683: QP-Prostate CAD

    U.S. Food and Drug Administration - Published 2025-03-18 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. QP-Prostate® CAD model card (K242683)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. QP-Prostate official product page

    Quibim - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

  8. Quibim: Security and Privacy Statement

    Quibim - Accessed 2026-10-27

    Scope: security

Research history

  1. K242683 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241770

Prostate MR AI (VA10A)

Siemens Healthcare GmbH

Authorized purpose: Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior treatment, using PI-RADS-oriented review; it is not the sole basis for diagnosis or management.

Modality
MRI
Anatomy
Prostate
Decision
2025-03-05
FDA-cleared K212783

ProstatID

ScanMed, LLC

Authorized purpose: Concurrent CADe/CADx reading aid for qualified physicians interpreting prostate MRI in adult males undergoing screening or clinical MRI, including high-risk screening or diagnostic imaging, to identify prostate abnormalities and regions suspicious for cancer and assess their likelihood of malignancy.

Modality
MRI
Anatomy
Prostate
Decision
2022-07-08
FDA-cleared K233196

Medihub Prostate

JLK Inc.

Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.

Modality
MRI
Anatomy
Prostate
Decision
2024-06-21

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history